Shark cartilage
This article was originally published in The Tan Sheet
Executive Summary
Saint Foy, Quebec-based AEterna Labs selected by the National Cancer Institute to conduct Phase III trials of the biotech lab's angiogenesis inhibitor AE-941/Neovastat, a liquid shark cartilage extract. The trials will attempt to evaluate the agent in the treatment of cancer, and will be conducted in hospitals throughout the U.S. and Canada beginning in early 1999. The studies are to include a double-blind, placebo-controlled trial administered to several hundred cancer patients
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: